<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">tumors</journal-id><journal-title-group><journal-title xml:lang="ru">Malignant tumours</journal-title><trans-title-group xml:lang="en"><trans-title>Malignant tumours</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2224-5057</issn><issn pub-type="epub">2587-6813</issn><publisher><publisher-name>Rosoncoweb</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.18027/2224-5057-2017-3s1-41-46</article-id><article-id custom-type="elpub" pub-id-type="custom">tumors-378</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Статьи</subject></subj-group></article-categories><title-group><article-title>Роль современных технологий послеоперационной лучевой терапии в комбинированном лечении немелкоклеточного рака легкого</article-title><trans-title-group xml:lang="en"><trans-title></trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Солодкий</surname><given-names>В. А.</given-names></name></name-alternatives><bio xml:lang="ru"><p>д. м. н., профессор, академик РАН, директор</p></bio><email xlink:type="simple">director@rncrr.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Сотников</surname><given-names>В. М.</given-names></name></name-alternatives><bio xml:lang="ru"><p>д. м. н., проф., зав. лабораторией лучевой терапии научно-исследовательского отдела инновационных технологий радиотерапии и химиолучевого лечения злокачественных новообразований</p></bio><email xlink:type="simple">vmsotnikov@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Паньшин</surname><given-names>Г. А.</given-names></name></name-alternatives><bio xml:lang="ru"><p>д. м. н., проф., руководитель отдела инновационных технологий радиотерапии и химиолучевого лечения злокачественных новообразований</p></bio><email xlink:type="simple">g.a.panshin@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Троценко</surname><given-names>С. Д.</given-names></name></name-alternatives><bio xml:lang="ru"><p>к. м. н., врач-радиолог отделения дистанционной лучевой терапии клиники радиотерапии</p></bio><email xlink:type="simple">trotsenkosd87@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Харченко</surname><given-names>В. П.</given-names></name></name-alternatives><bio xml:lang="ru"><p>д. м. н., профессор, академик РАН, научный руководитель</p></bio><email xlink:type="simple">director@rncrr.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Чхиквадзе</surname><given-names>В. Д.</given-names></name></name-alternatives><email xlink:type="simple">vdc@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Нуднов</surname><given-names>Н. В.</given-names></name></name-alternatives><bio xml:lang="ru"><p>д. м. н., профессор, зам директора</p></bio><email xlink:type="simple">nudnov@rncrr.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Моргунов</surname><given-names>А. А.</given-names></name></name-alternatives><bio xml:lang="ru"><p>старший научный сотрудник организационного отдела</p></bio><email xlink:type="simple">al-morgunov@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff xml:lang="ru" id="aff-1"><institution>ФГБУ «Российский научный центр рентгенорадиологии»</institution><country>Russian Federation</country></aff><pub-date pub-type="collection"><year>2017</year></pub-date><pub-date pub-type="epub"><day>17</day><month>11</month><year>2017</year></pub-date><volume>0</volume><issue>3s1</issue><fpage>41</fpage><lpage>46</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Солодкий В.А., Сотников В.М., Паньшин Г.А., Троценко С.Д., Харченко В.П., Чхиквадзе В.Д., Нуднов Н.В., Моргунов А.А., 2017</copyright-statement><copyright-year>2017</copyright-year><copyright-holder xml:lang="ru">Солодкий В.А., Сотников В.М., Паньшин Г.А., Троценко С.Д., Харченко В.П., Чхиквадзе В.Д., Нуднов Н.В., Моргунов А.А.</copyright-holder><copyright-holder xml:lang="en">Солодкий В.А., Сотников В.М., Паньшин Г.А., Троценко С.Д., Харченко В.П., Чхиквадзе В.Д., Нуднов Н.В., Моргунов А.А.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.malignanttumors.org/jour/article/view/378">https://www.malignanttumors.org/jour/article/view/378</self-uri><abstract><p>.</p></abstract></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Вальков М. Ю., Скрипач Ю. В., Соловьева Е. П. с соавт. Методы лечения и исходы при местно-распространенном раке легкого III стадии: популяционный анализ. // Вестник РНЦРР. – 2014. – № 9. – стр. 9.</mixed-citation><mixed-citation xml:lang="en">Вальков М. Ю., Скрипач Ю. В., Соловьева Е. П. с соавт. Методы лечения и исходы при местно-распространенном раке легкого III стадии: популяционный анализ. // Вестник РНЦРР. – 2014. – № 9. – стр. 9.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Миллер С. В., Тузиков С. А., Завьялов А. А. с соавт. Анализ осложнений комбинированного лечения немелкоклеточного рака легкого. // Сибирский онкологический журнал. – 2007. – Т. 4. – С. 50–56.</mixed-citation><mixed-citation xml:lang="en">Миллер С. В., Тузиков С. А., Завьялов А. А. с соавт. Анализ осложнений комбинированного лечения немелкоклеточного рака легкого. // Сибирский онкологический журнал. – 2007. – Т. 4. – С. 50–56.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Михина З. П., Горбунова В. А., Ткачев С. И. с соавт. Современная химиолучевая терапия больных с немелкоклеточным раком легкого. // Медицинская радиология и радиационная безопасность. – 2012. – Т. 57. – № 2. – С. 26–30.</mixed-citation><mixed-citation xml:lang="en">Михина З. П., Горбунова В. А., Ткачев С. И. с соавт. Современная химиолучевая терапия больных с немелкоклеточным раком легкого. // Медицинская радиология и радиационная безопасность. – 2012. – Т. 57. – № 2. – С. 26–30.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Паршин В. Д., Белов Ю. В., Выжгина М. А. Хирургия злокачественных опухолей легкого у больных старше 70 лет. // Хирургия. Журнал им. Н. И. Пирогова. – 2010. – № 10. – С. 11–16.</mixed-citation><mixed-citation xml:lang="en">Паршин В. Д., Белов Ю. В., Выжгина М. А. Хирургия злокачественных опухолей легкого у больных старше 70 лет. // Хирургия. Журнал им. Н. И. Пирогова. – 2010. – № 10. – С. 11–16.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Петерсон Б. Е. Рак легкого. // М. Медицина. – 1971. – С. 24–26.</mixed-citation><mixed-citation xml:lang="en">Петерсон Б. Е. Рак легкого. // М. Медицина. – 1971. – С. 24–26.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Солодкий В. А., Харченко В. П., Чхиквадзе В. Д. и др. Результаты хирургического и комбинированного лечения немелкоклеточного рака легкого с послеоперационной лучевой терапией в режиме гипофракционирования. сообщение II. Безрецидивная выживаемость и выживаемость без локорегионарного рецидива. // Вопросы онкологии. – 2016. – Т. 62. – № 1. – С. 72–78.</mixed-citation><mixed-citation xml:lang="en">Солодкий В. А., Харченко В. П., Чхиквадзе В. Д. и др. Результаты хирургического и комбинированного лечения немелкоклеточного рака легкого с послеоперационной лучевой терапией в режиме гипофракционирования. сообщение II. Безрецидивная выживаемость и выживаемость без локорегионарного рецидива. // Вопросы онкологии. – 2016. – Т. 62. – № 1. – С. 72–78.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Трахтенберг А. X., Колбанов К. И., Вурсол Д. А. Расширенные и комбинированные операции при местно-распространенном немелкоклеточном раке легкого. // Российский онкологический журнал. – 2007. – № 2. – С. 9–14.</mixed-citation><mixed-citation xml:lang="en">Трахтенберг А. X., Колбанов К. И., Вурсол Д. А. Расширенные и комбинированные операции при местно-распространенном немелкоклеточном раке легкого. // Российский онкологический журнал. – 2007. – № 2. – С. 9–14.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Троценко С. Д., Солодкий В. А., Сотников В. М. и др. Результаты хирургического и комбинированного лечения немелкоклеточного рака легкого с послеоперационной лучевой терапией в режиме гипофракционирования. Общая и болезнь-специфичная выживаемость. // Вопросы онкологии. – 2015. – Т. 61. – № 1. – С. 71–76.</mixed-citation><mixed-citation xml:lang="en">Троценко С. Д., Солодкий В. А., Сотников В. М. и др. Результаты хирургического и комбинированного лечения немелкоклеточного рака легкого с послеоперационной лучевой терапией в режиме гипофракционирования. Общая и болезнь-специфичная выживаемость. // Вопросы онкологии. – 2015. – Т. 61. – № 1. – С. 71–76.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Харченко В. П., Волохов В. Э. Комбинированное лечение больных раком легкого. // Материалы научной работы по онкологии. – 1966. –С. 38–42.</mixed-citation><mixed-citation xml:lang="en">Харченко В. П., Волохов В. Э. Комбинированное лечение больных раком легкого. // Материалы научной работы по онкологии. – 1966. –С. 38–42.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Харченко В. П., Кузьмин И. В. Рак легкого. Руководство для врачей. // М.: Медицина. – 1994. – стр. 92.</mixed-citation><mixed-citation xml:lang="en">Харченко В. П., Кузьмин И. В. Рак легкого. Руководство для врачей. // М.: Медицина. – 1994. – стр. 92.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Харченко В. П., Чхиквадзе В. Д., Паньшин Г. А. Комбинированое и хирургическое лечение больных раком легкого. // Вестник Московского Онкологического Общества. – 2009. – № 9. – стр. 5.</mixed-citation><mixed-citation xml:lang="en">Харченко В. П., Чхиквадзе В. Д., Паньшин Г. А. Комбинированое и хирургическое лечение больных раком легкого. // Вестник Московского Онкологического Общества. – 2009. – № 9. – стр. 5.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Яблонский П. К., Петров А. С. Видеомедиастиноскопия и другие методы N-стадирования в хирургии рака легкого // Геотар-Медиа. – 2015. – С. 26–28.</mixed-citation><mixed-citation xml:lang="en">Яблонский П. К., Петров А. С. Видеомедиастиноскопия и другие методы N-стадирования в хирургии рака легкого // Геотар-Медиа. – 2015. – С. 26–28.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Arriagada R., Auperin A., Burdett S. et al: Adjuvant chemotherapy with or without postoperative radiotherapy in operable non-small-cell lung cancer: two meta-analyses of individual patient data. // Lancet. – 2010. – V. 375. – P. 1267–1277.</mixed-citation><mixed-citation xml:lang="en">Arriagada R., Auperin A., Burdett S. et al: Adjuvant chemotherapy with or without postoperative radiotherapy in operable non-small-cell lung cancer: two meta-analyses of individual patient data. // Lancet. – 2010. – V. 375. – P. 1267–1277.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Astudillo J., Conill C. Role of postoperative radiation therapy in stage IIIa non-small cell lung cancer. // Ann Thorac Surg. – 1990. – V. 50. – P. 618–623.</mixed-citation><mixed-citation xml:lang="en">Astudillo J., Conill C. Role of postoperative radiation therapy in stage IIIa non-small cell lung cancer. // Ann Thorac Surg. – 1990. – V. 50. – P. 618–623.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Billiet C., Decaluwe H., Peeters S. et al. Modern post-operative radiotherapy for stage III non-small cell lung cancer may improve local control and survival: A meta-analysis. // Radiother. Oncol. – 2013. – V. 110. – № 1. – P. 3–8.</mixed-citation><mixed-citation xml:lang="en">Billiet C., Decaluwe H., Peeters S. et al. Modern post-operative radiotherapy for stage III non-small cell lung cancer may improve local control and survival: A meta-analysis. // Radiother. Oncol. – 2013. – V. 110. – № 1. – P. 3–8.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Billiet C., Gouw Z., Defraene G. et al. Postoperative radiotherapy in resected ypN2 stage III-N2 non-small cell lung cancer: can modern conformal radiotherapy compensate for the poor outcome? // Annals of Oncology. – 2014. – V25. – № 4. – P. 417–425.</mixed-citation><mixed-citation xml:lang="en">Billiet C., Gouw Z., Defraene G. et al. Postoperative radiotherapy in resected ypN2 stage III-N2 non-small cell lung cancer: can modern conformal radiotherapy compensate for the poor outcome? // Annals of Oncology. – 2014. – V25. – № 4. – P. 417–425.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Chung C. K., Stryker J. A., O”Neill M. Jr. et al. Evaluation of adjuvant postoperative radiotherapy for lung cancer. // Int J Radiat Oncol Biol Phys. – 1982. – Т. 8. – P. 1877–1880.</mixed-citation><mixed-citation xml:lang="en">Chung C. K., Stryker J. A., O”Neill M. Jr. et al. Evaluation of adjuvant postoperative radiotherapy for lung cancer. // Int J Radiat Oncol Biol Phys. – 1982. – Т. 8. – P. 1877–1880.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Corso C. D., Rutter C. E., Wilson L. D. et al. Re-evaluation of the Role of Cancer Using the National Cancer Database. // J. Thorac. Oncol. – 2015. – V. 10. – P. 148–155.</mixed-citation><mixed-citation xml:lang="en">Corso C. D., Rutter C. E., Wilson L. D. et al. Re-evaluation of the Role of Cancer Using the National Cancer Database. // J. Thorac. Oncol. – 2015. – V. 10. – P. 148–155.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Douillard J. Y., Rosell R., De Lena M. et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. // Lancet Oncol. – 2006. – V. 7. – P. 719–727.</mixed-citation><mixed-citation xml:lang="en">Douillard J. Y., Rosell R., De Lena M. et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. // Lancet Oncol. – 2006. – V. 7. – P. 719–727.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Fan C, Gao S, Hui Z, Liang J, Lv J, Wang X et al (2013) Risk factors for locoregional recurrence in patients with resected N1 non-small cell lung cancer: a retrospective study to identify patterns of failure and implications for adjuvant radiotherapy. // Radiat Oncol. – V. 8. – P. 286.</mixed-citation><mixed-citation xml:lang="en">Fan C, Gao S, Hui Z, Liang J, Lv J, Wang X et al (2013) Risk factors for locoregional recurrence in patients with resected N1 non-small cell lung cancer: a retrospective study to identify patterns of failure and implications for adjuvant radiotherapy. // Radiat Oncol. – V. 8. – P. 286.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Goldstraw P., Crowley J., Chansky K. et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours // J. Thorac. Oncol. – 2007. – V. 2. – P. 706–714.</mixed-citation><mixed-citation xml:lang="en">Goldstraw P., Crowley J., Chansky K. et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours // J. Thorac. Oncol. – 2007. – V. 2. – P. 706–714.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Ichinose Y., Kato H., Koike T. et al. Overall survival and local recurrence of 406 completely resected stage IIIa-N2 non-small cell lung cancer patients: Questionnaire survey of the Japan Clinical Oncology Group to plan for clinical trials. // Lung Cancer. – 2001. – V. 34. – P. 29–36.</mixed-citation><mixed-citation xml:lang="en">Ichinose Y., Kato H., Koike T. et al. Overall survival and local recurrence of 406 completely resected stage IIIa-N2 non-small cell lung cancer patients: Questionnaire survey of the Japan Clinical Oncology Group to plan for clinical trials. // Lung Cancer. – 2001. – V. 34. – P. 29–36.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">International Adjuvant Lung Cancer Trial Collaborative Group. Arriagada R., Bergman B., Dunant A. et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. // N Engl J Med. – 2004. – V. 350. – P. 351–360.</mixed-citation><mixed-citation xml:lang="en">International Adjuvant Lung Cancer Trial Collaborative Group. Arriagada R., Bergman B., Dunant A. et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. // N Engl J Med. – 2004. – V. 350. – P. 351–360.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Jemal A., Bray F., Center M. M. et al. Global cancer statistics. CA Cancer J Clin. – 2011. –V. 61. –P. 69–90.</mixed-citation><mixed-citation xml:lang="en">Jemal A., Bray F., Center M. M. et al. Global cancer statistics. CA Cancer J Clin. – 2011. –V. 61. –P. 69–90.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Kelsey C. R., Marks L. B., Hollis D. et al. Local recurrence after surgery for early stage lung cancer: An 11-year experience with 975 patients. // Cancer. – 2000. – V. 115. – P. 5218–5227.</mixed-citation><mixed-citation xml:lang="en">Kelsey C. R., Marks L. B., Hollis D. et al. Local recurrence after surgery for early stage lung cancer: An 11-year experience with 975 patients. // Cancer. – 2000. – V. 115. – P. 5218–5227.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Kepka L., Bujko K., Orlowski T. M. et al. Cardiopulmonary morbidity and quality of life in non-small cell lung cancer patients treated with or without postoperative radiotherapy. // Radiother. Oncol. – 2011. – V. 98. – № 2. – P. 238–243.</mixed-citation><mixed-citation xml:lang="en">Kepka L., Bujko K., Orlowski T. M. et al. Cardiopulmonary morbidity and quality of life in non-small cell lung cancer patients treated with or without postoperative radiotherapy. // Radiother. Oncol. – 2011. – V. 98. – № 2. – P. 238–243.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Kirsh M. M., Sloan H. Mediastinal metastases in bronchogenic carcinoma: Influence of postoperative irradiation, cell type and ocation. // Ann Thorac. – 1982. – Т. 33. – P. 459–463.</mixed-citation><mixed-citation xml:lang="en">Kirsh M. M., Sloan H. Mediastinal metastases in bronchogenic carcinoma: Influence of postoperative irradiation, cell type and ocation. // Ann Thorac. – 1982. – Т. 33. – P. 459–463.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Kolodziejczyk М., Bujko K., Michalski W., Kepka L. Incidence of isolated nodal failure in non-small cell lung cancer patients included in a prospective study of the value of PET – CT. // Radiotherapy and Oncology. – 2012. – V. 104. – № 1. – P. 58–61.</mixed-citation><mixed-citation xml:lang="en">Kolodziejczyk М., Bujko K., Michalski W., Kepka L. Incidence of isolated nodal failure in non-small cell lung cancer patients included in a prospective study of the value of PET – CT. // Radiotherapy and Oncology. – 2012. – V. 104. – № 1. – P. 58–61.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Lally B. E., Detterbeck F. C., Geiger A. M. et al. The risk of death from heart disease in patients with non-small cell lung cancer who receive postoperative radiotherapy: analysis of the Surveillance, Epidemiology, and End Results database. // Cancer. – 2007. – V. 110. – № 4. – P. 911–917.</mixed-citation><mixed-citation xml:lang="en">Lally B. E., Detterbeck F. C., Geiger A. M. et al. The risk of death from heart disease in patients with non-small cell lung cancer who receive postoperative radiotherapy: analysis of the Surveillance, Epidemiology, and End Results database. // Cancer. – 2007. – V. 110. – № 4. – P. 911–917.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Landreneau J. P., Schuchert M. J., Weyant R. et al. Anatomic segmentectomy and brachytherapy mesh implantation for clinical stage I non-small cell lung cancer (NSCLC). // Surgery. – 2014. – V. 155. – P. 340–346.</mixed-citation><mixed-citation xml:lang="en">Landreneau J. P., Schuchert M. J., Weyant R. et al. Anatomic segmentectomy and brachytherapy mesh implantation for clinical stage I non-small cell lung cancer (NSCLC). // Surgery. – 2014. – V. 155. – P. 340–346.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Machtay M., Lee J. H., Shrager J. B., Kaiser L. R., Glatstein E. Risk of Death From Intercurrent Disease Is Not Excessively Increased by Modern Postoperative Radiotherapy for High-Risk Resected Non – Small-Cell Lung Carcinoma. // Journal of Clinical Oncology. – 2001. – V. 19. – № 19. – P. 3912–3917.</mixed-citation><mixed-citation xml:lang="en">Machtay M., Lee J. H., Shrager J. B., Kaiser L. R., Glatstein E. Risk of Death From Intercurrent Disease Is Not Excessively Increased by Modern Postoperative Radiotherapy for High-Risk Resected Non – Small-Cell Lung Carcinoma. // Journal of Clinical Oncology. – 2001. – V. 19. – № 19. – P. 3912–3917.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Patela S. H., Mab Y., Wernickea A. G. et al. Evidence supporting contemporary post-operative radiation therapy (PORT) using linear accelerators in N2 lung cancer. // Lung Cancer. – 2014. – V. 84. – P. 156–160.</mixed-citation><mixed-citation xml:lang="en">Patela S. H., Mab Y., Wernickea A. G. et al. Evidence supporting contemporary post-operative radiation therapy (PORT) using linear accelerators in N2 lung cancer. // Lung Cancer. – 2014. – V. 84. – P. 156–160.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Paterson R., Russell M. H. Clinical trials in malignant disease. Part-IV-Lung Cancer. Value of post-operative radiotherapy. // Clinical radiology. – 1962. – P. 141–144.</mixed-citation><mixed-citation xml:lang="en">Paterson R., Russell M. H. Clinical trials in malignant disease. Part-IV-Lung Cancer. Value of post-operative radiotherapy. // Clinical radiology. – 1962. – P. 141–144.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Pignon J. P., Tribodet H., Scagliotti G. V. et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE collaborative group. // J Clin Oncol. – 2008. – V. 26. – P. 3552–3559.</mixed-citation><mixed-citation xml:lang="en">Pignon J. P., Tribodet H., Scagliotti G. V. et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE collaborative group. // J Clin Oncol. – 2008. – V. 26. – P. 3552–3559.</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">PORT Meta-analysis Trialists Group. Postoperative radiotherapy in non-small-cell lung cancer: Systematic review and meta-analysis of individual patient data from nine randomised controlled trials. // Lancet. – 1998. – V. 352. – P. 257–263.</mixed-citation><mixed-citation xml:lang="en">PORT Meta-analysis Trialists Group. Postoperative radiotherapy in non-small-cell lung cancer: Systematic review and meta-analysis of individual patient data from nine randomised controlled trials. // Lancet. – 1998. – V. 352. – P. 257–263.</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Robinson C. G., Patel A. P., Bradley J. D. et al. Postoperative Radiotherapy for Pathologic N2 Non – Small-Cell Lung Cancer Treated With Adjuvant Chemotherapy: A Review of the National Cancer Data Base. // J. Clin. Oncol. – 2015. – V. 34. – P. 2–8.</mixed-citation><mixed-citation xml:lang="en">Robinson C. G., Patel A. P., Bradley J. D. et al. Postoperative Radiotherapy for Pathologic N2 Non – Small-Cell Lung Cancer Treated With Adjuvant Chemotherapy: A Review of the National Cancer Data Base. // J. Clin. Oncol. – 2015. – V. 34. – P. 2–8.</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Sawyer T. E., Bonner J. A., Gould P. M. et al. Effectiveness of postoperative irradiation in stage IIIA non-small cell lung cancer according to regression tree analyses of recurrence risks. // Ann Thorac Surg. – 1997. – Т. 64. – P. 1402–1408.</mixed-citation><mixed-citation xml:lang="en">Sawyer T. E., Bonner J. A., Gould P. M. et al. Effectiveness of postoperative irradiation in stage IIIA non-small cell lung cancer according to regression tree analyses of recurrence risks. // Ann Thorac Surg. – 1997. – Т. 64. – P. 1402–1408.</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Su S., Scott W. J., Allen M. S. et al. Patterns of survival and recurrence after surgical treatment of early stage non – small cell lung carcinoma in the ACOSOG Z0030 (ALLIANCE) trial. // J. Thorac Cardiovasc. Surg. – 2014. – V. 147. – P. 747–753.</mixed-citation><mixed-citation xml:lang="en">Su S., Scott W. J., Allen M. S. et al. Patterns of survival and recurrence after surgical treatment of early stage non – small cell lung carcinoma in the ACOSOG Z0030 (ALLIANCE) trial. // J. Thorac Cardiovasc. Surg. – 2014. – V. 147. – P. 747–753.</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Thames H. D. Postoperative radiotherapy of non-small cell lung cancer: a flow in the PORT meta-analysis. // Progress in Radiotherapy VII. – Bologna. – 2002. – P. 9–16.</mixed-citation><mixed-citation xml:lang="en">Thames H. D. Postoperative radiotherapy of non-small cell lung cancer: a flow in the PORT meta-analysis. // Progress in Radiotherapy VII. – Bologna. – 2002. – P. 9–16.</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Wakelee H. A., Stephenson P., Keller S. M. et al. Post-operative radiotherapy or chemoradiotherapy following resection of stages II and IIIA non-small cell lung cancer does not increase the expected risk of death from intercurrent disease in Eastern Cooperative Oncology Group trial E3590. // Lung Cancer. – 2005. – V. 48. – P. 389–397.</mixed-citation><mixed-citation xml:lang="en">Wakelee H. A., Stephenson P., Keller S. M. et al. Post-operative radiotherapy or chemoradiotherapy following resection of stages II and IIIA non-small cell lung cancer does not increase the expected risk of death from intercurrent disease in Eastern Cooperative Oncology Group trial E3590. // Lung Cancer. – 2005. – V. 48. – P. 389–397.</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Wang Y., Li B., Huang W. et al. Pattern of lymph node metastases and its implication in radiotherapeutic clinical target volume in patients with non-small-cell lung cancer: a study of 2062 cases. // Br. J. Radiol. – 2015. – V. 88. – P. 1–8</mixed-citation><mixed-citation xml:lang="en">Wang Y., Li B., Huang W. et al. Pattern of lymph node metastases and its implication in radiotherapeutic clinical target volume in patients with non-small-cell lung cancer: a study of 2062 cases. // Br. J. Radiol. – 2015. – V. 88. – P. 1–8</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Warren M., Webster G., Ryder D. et al. An isotoxic planning comparison study for stage II-III non-small cell lung cancer: is intensity-modulated radiotherapy the answer? // Clinical Oncology. – 2014. – V. 26. – № 8. – P. 461–467.</mixed-citation><mixed-citation xml:lang="en">Warren M., Webster G., Ryder D. et al. An isotoxic planning comparison study for stage II-III non-small cell lung cancer: is intensity-modulated radiotherapy the answer? // Clinical Oncology. – 2014. – V. 26. – № 8. – P. 461–467.</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">Winton T., Livingston R., Johnson D. et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. //</mixed-citation><mixed-citation xml:lang="en">Winton T., Livingston R., Johnson D. et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. //</mixed-citation></citation-alternatives></ref><ref id="cit44"><label>44</label><citation-alternatives><mixed-citation xml:lang="ru">N. Engl. J. Med. – 2005. – V. 352. – № 25. – P. 2589–2597.</mixed-citation><mixed-citation xml:lang="en">N. Engl. J. Med. – 2005. – V. 352. – № 25. – P. 2589–2597.</mixed-citation></citation-alternatives></ref><ref id="cit45"><label>45</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang Y., Sun Y., Xiang J. et al. A prediction model for N2 disease in T1 non – small cell lung cancer. // J. Thorac Cardiovasc. Surg. – 2012. – V. 144. – P. 1360–1364.</mixed-citation><mixed-citation xml:lang="en">Zhang Y., Sun Y., Xiang J. et al. A prediction model for N2 disease in T1 non – small cell lung cancer. // J. Thorac Cardiovasc. Surg. – 2012. – V. 144. – P. 1360–1364.</mixed-citation></citation-alternatives></ref><ref id="cit46"><label>46</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang Y., Sun Y., Xiang J. et al. A clinicopathologic prediction model for postoperative recurrence in stage Ia non – small cell lung cancer. // J. Thorac Cardiovasc. Surg. – 2014. – V. 195. – № 2. – P. 1–7.</mixed-citation><mixed-citation xml:lang="en">Zhang Y., Sun Y., Xiang J. et al. A clinicopathologic prediction model for postoperative recurrence in stage Ia non – small cell lung cancer. // J. Thorac Cardiovasc. Surg. – 2014. – V. 195. – № 2. – P. 1–7.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
